Lattice Biologics Ltd.
LBLTF
$0.00
$0.000.00%
OTC PK
| 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -38.06% | -32.19% | 52.36% | 12.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -38.06% | -32.19% | 52.36% | 12.54% |
| Cost of Revenue | -- | 28.63% | -28.61% | -25.43% | 25.65% |
| Gross Profit | -- | -83.37% | -34.66% | 416.96% | -7.77% |
| SG&A Expenses | -92.34% | 21.64% | 10.86% | -72.13% | 0.09% |
| Depreciation & Amortization | -- | 36.98% | -15.12% | 245.58% | -0.38% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -96.47% | 26.21% | -9.41% | -29.73% | 10.58% |
| Operating Income | 88.65% | -440.08% | -347.98% | 106.85% | -6.46% |
| Income Before Tax | 91.93% | 54.39% | -284.98% | 64.17% | -9.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 91.93% | 54.39% | -284.98% | 64.17% | -9.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.93% | 54.39% | -284.98% | 64.17% | -9.79% |
| EBIT | 88.65% | -440.08% | -347.98% | 106.85% | -6.46% |
| EBITDA | 121.68% | -1,561.03% | -181.85% | 136.20% | -23.10% |
| EPS Basic | 93.75% | 67.03% | -200.00% | 73.24% | -3.23% |
| Normalized Basic EPS | 95.00% | 66.67% | -160.00% | 64.44% | -5.26% |
| EPS Diluted | 93.75% | 67.03% | -200.00% | 73.24% | -3.23% |
| Normalized Diluted EPS | 95.00% | 66.67% | -160.00% | 64.44% | -5.26% |
| Average Basic Shares Outstanding | 28.82% | 37.19% | 37.19% | 32.54% | 6.50% |
| Average Diluted Shares Outstanding | 28.82% | 37.19% | 37.19% | 32.54% | 6.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |